Views: 252 Downloads: 31

Hoda Jelodar , Ladan Fatahi , Parvin Kheradmand , Mohsen Sarkarian

Abstract

The transcription factor GATA-binding protein 3 (GATA3) is helpful as a marker to distinguish urothelial bladder carcinoma (UBC) from other cancers. Hence, the current study was done with the purpose of evaluating the expression of the tumor marker GATA3 in the progression of UBC. In this cross-sectional study, the total number of UBC samples were collected in the period of 2018-2019. First, the demographic and clinical data of each sample, such as age and gender of the patients, depth of tumor, grade of tumor, and type of tumor variant, were extracted from the patient record and recorded. Samples were stained in this manner to examine GATA3 immunohistochemistry (IHC) with labeled antibodies. Finally, 39 patients were included. There was no statistically significant association observed (P > 0.05) between age, gender, tumor grade, muscular invasion, and GATA3 expression. The relation was performed, and depending on the level of significance, it could be said that there was no significant association (P=0.54). 2 individuals were GATA3 expression negative and high grade, 16 individuals were diffuse strong and high grade, 20 individuals were diffuse strong and low grade, and one individual was heterogeneous strong.

In conclusion, a higher percentage of positive expression of GATA3 was observed in the present study compared to other studies performed in this field. However, due to the lack of correlation between its expression and demographic information, as well as the clinicopathological factors of bladder urothelial carcinoma, GATA3 is not a reliable marker to determine prognosis in this cancer type‎.